SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as investors highlight its role as essential decentralized finance infrastructure, bolstered by a recent partnership with the U.S. Department of Commerce to provide macroeconomic data on-chain. The community is actively discussing the project's strong institutional backing, revenue-sharing model through token buybacks, and its growing importance within the Real World Asset (RWA) sector.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

The 4CHAN token is trending as a cultural index, with community members branding it the "Bitcoin of memecoins" due to its origins as the birthplace of major internet memes. While some retail traders are debating its volatility and long-term potential, the community is actively encouraging others to accumulate during market dips and hold through structural price fluctuations.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing community attention as traders highlight its recent price resilience and YTD outperformance against Bitcoin, fueling speculation of a major breakout. Conversations are dominated by anticipation for the upcoming 2026 'Layla' network upgrade, with many users debating its potential to reclaim status as a top-tier peer-to-peer electronic cash platform while others remain skeptical of its long-term momentum.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as investors debate the potential for a recovery amid active discussions about its decentralized AI agent infrastructure and recent volatility. The community remains polarized, with some focused on long-term utility and accumulation opportunities while others express frustration over price performance and the ongoing fallout from the ASI merger.

WorldFinancial

World Liberty Financial ($WLFI) is seeing intense community debate and volatility as traders react to a recent Congressional probe regarding its $500 million stake sale to UAE-affiliated investors. While critics characterize the project as a high-risk scam with restricted liquidity, proponents argue that the upcoming product milestones and institutional partnerships represent a strategic long-term play in the decentralized finance sector.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending as investors focus on an upcoming Phase 3 SENTRY trial data readout for myelofibrosis in March 2026, which serves as a critical, binary catalyst for the company. The community remains deeply divided, with many expressing frustration over the stock's significant decline and management's past execution, while others closely watch for institutional accumulation and potential M&A interest as a pathway to restore shareholder value.

EQT Corp. is a natural gas production company, which engages in the provision of supply, transmission, and distribution of natural gas. The company was founded in 1888 and is headquartered in Pittsburgh, PA.

EQT Corp

EQT Corp is drawing investor attention as it reports a significant earnings beat and raises production guidance, highlighting strong operational efficiency and cost management. The community is actively debating the company's long-term value proposition as it positions itself to capitalize on growing natural gas demand from AI data centers and evolving infrastructure needs.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is trending as the community debates its long-term utility in tokenized banking and interoperability infrastructure compared to its stagnant price action. Investors are actively discussing the significance of institutional adoption, such as participation in central bank pilots, while remaining divided between those aggressively accumulating on dips and others frustrated by the persistent consolidation.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy is experiencing significant volatility driven by a major earnings miss and investor caution ahead of potential equity dilution, while the long-term bullish thesis remains centered on its role as the only licensed U.S. producer of HALEU fuel for critical nuclear infrastructure. The community is actively debating the company's valuation versus its strategic necessity, with many traders focused on technical support levels and the potential for a recovery as the sector benefits from sustained federal funding and increasing energy demands from AI data centers.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron is trending as investors weigh strong earnings and high-growth potential in its immunology and oncology pipelines against ongoing regulatory scrutiny at a third-party manufacturing facility. Community sentiment remains mixed, with bullish long-term investors pointing to strong fundamentals and potential label expansions, while traders express frustration over the stock's volatility and recent supply-chain related delays.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Senseis Board of Directors granted a new employee an option to purchase 166,435 shares of the Companys...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Senseis Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893...

Small Cap Stocks To Add to Your Watchlist - February 18th

Rackspace Technology, Direxion Daily PLTR Bear 1X Shares, Spring Valley Acquisition, Direxion Daily MU Bull 2X Shares, Sensei Biotherapeutics, Inflection Point Acquisition Corp. II, and Direxion...

<ul class="summary-bullets"><li>The company also secured a private placement financing worth around $200 million.</li><li>Sensei Biotherapeutics plans to use the majority of the proceeds to advance PIKTOR.</li><li>Remaining funds will be used for the development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.</li></ul>Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.<a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> rose to its highest since May 2024 and recorded its biggest-ever intraday gains. Trading in the stock was twice halted after the opening bell, according to Nasdaq data.The acquisition adds Faeth’s lead investigational therapy, PIKTOR, an all-oral drug combination that targets tumor metabolism and blocks multiple points in the PI3K/AKT/mTOR pathway, a critical cell signaling system that regulates cell survival, growth, and division.“In the PI3K pathway, the field has repeatedly run into the same constraint. Single-node inhibitors force a tradeoff between efficacy and tolerability. PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability,” said Anand Parikh, Co-founder of Faeth Therapeutics and the new COO and director of Sensei.<h2 class="st-heading-2">$200 Million Private Placement</h2>Sensei Biotherapeutics also secured private placement financing, worth about $200 million. The company plans to use most of the capital to advance PIKTOR, including topline results from an ongoing Phase 2 trial in second-line advanced endometrial cancer and the launch of a Phase 1b study in HR+/HER2- advanced breast cancer, both anticipated by the end of 2026.Remaining funds will support general corporate initiatives and the continued development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.The private placement attracted participation from B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, and Vivo Capital, among other life sciences funds and institutional investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish,’ amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SNSE_jpg_53f7157d12.webp" alt="SNSE.jpg">One user expects the stock to “go up big” if it holds above the $25.4 to $25.5 support. It is currently trading at around $28.<stembedurl>https://stocktwits.com/brewstocks123/message/645236001</stembedurl>Another user expects the stock to climb to $44 by the end of the session.<stembedurl>https://stocktwits.com/FreyBentos/message/645238839</stembedurl>The stock has gained around 160% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rxt-stock-soars-pre-market-palantir-connection/cZR0r6BR4vX">RXT Stock Soared 275% Today – What’s The Connection&nbsp;With Palantir?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Representative image of a trending stock chart.

 SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition

Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.

Equity

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Sensei Biotherapeutics Stock Soars 230% After Faeth Deal

SNSE up on acquisition of Faeth Therapeutics, $200M private placement, and addition of PIKTOR to pipeline targeting cancer.read more...

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (Faeth), a clinical-stage biotechnology company developing multi-node therapies that target...

Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder James Peyer Sells 3,105 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder James Peyer sold 3,105 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average...

James Peyer Sells 5,000 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder James Peyer sold 5,000 shares of the firm's stock in a transaction on Thursday, December 4th. The shares were sold at an...

What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After Hours Jump?

Sensei Biotherapeutics surged in after-hours trading Thursday, with strong recent gains and ongoing shareholder activity drawing attention.read more...

<ul class="summary-bullets"><li>The company stated that it anticipates reducing its workforce to conserve cash as part of its strategic review.</li><li>The company said that it decided not to initiate a new clinical study of Solnerstotug in cancer patients after reviewing “future funding needs and current capital markets environment.” &nbsp;</li></ul>Sensei Biotherapeutics, Inc. (SNSE) on Thursday said that its Board of Directors has determined to discontinue development of its lead product candidate, Solnerstotug, and initiate a comprehensive review of strategic alternatives.The Board came to the decision after extensive consideration, it said. The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations, Sensei <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/30/3177470/0/en/Sensei-Biotherapeutics-Announces-Initiation-of-Strategic-Review-to-Maximize-Shareholder-Value.html">said</a>. Further, there is no assurance that the review will result in a transaction, the company added.<h2 class="st-heading-2">Workforce Reduction Plans</h2>The company stated that it anticipates reducing its workforce to conserve cash as part of its strategic review. Details of the layoffs will be announced separately, the company said.Sensei Biotherapeutics, however, plans to retain a small team of employees to assist in the strategic review process and to manage a smooth transition of developmental activities. &nbsp;The company said that it decided not to initiate a new clinical study of Solnerstotug in cancer patients after reviewing “future funding needs and current capital markets environment.” The drug had demonstrated clinical activity in previous trials.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company rallied 5% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.SNSE stock is up 5% this year and down by 10% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options

The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, Sensei said.

The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations, Sensei said.


Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$4.81	--	--	N/A
Q3 '25	-$4.11	-$3.62	11.92%	BEAT
Q2 '25	-$5.60	-$3.91	30.18%	BEAT
Q1 '25	-$0.22	-$5.40	-2317.91%	MISSED
Q4 '24	-$0.28	-$0.31	-12.05%	MISSED

SNSE
Sensei Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest SNSE News

SNSESensei Biotherapeutics Inc